STTR Phase I: Advanced Microfluidic Devices for Point-of-Care COVID-19 Serological Testing

STTR 第一阶段：用于护理点 COVID-19 血清学检测的先进微流体设备

• 批准号: 2032222
• 负责人: Thomas Reilly
• 金额: $ 25.6万
• 依托单位: Access Sensor Technologies
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2022-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032222&HistoricalAwards=false
• 关键词: STTR; Phase; Advanced; Microfluidic; Devices

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project may reach millions of people and provide a key tool in safeguarding the public health through the COVID-19 pandemic. Sensitive, selective and quantitative detection usually requires complex laboratory-based methods and instrumentation to achieve consistent results; however, this project advances technologies to simplify the process. Antibody testing provides information regarding previous infections; a simple tool to detect presence at low concentrations enables better testing to manage social distancing needs. The proposed technology aims to make blood testing for SARS-Cov-2 simple and quantitative for two types of antibodies. The device will be developed to take patient samples directly with no complicated sample prep. Unique reagents will be created for selective detection of the SARS-CoV-2 antibodies. This Small Business Technology Transfer (STTR) Phase I project aims to develop the next generation of low-cost point of care immunoassay technology with direct application to infectious disease detection. The technology proposed here combines a new approach to controlling capillary flow driven systems applied to the steps of a traditional ELISA in a disposable device. The device developed in this project will detect SARSCoV-2 specific antibodies in patient samples, and will be able to provide information about the phase of the immune response of a patient. Additionally, adaption of ELISA-like enzymatic amplification into a point-of-care device will provide greater sensitivity and selectivity than traditional lateral flow assays, increasing assay sensitivity and improving detection of early infections. The immunoassays will be evaluated with deidentified patient samples and compared to state of the art laboratory-based detection methods.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小企业技术转让（STTR）第一阶段项目的更广泛影响/商业潜力可能惠及数百万人，并为在2019冠状病毒病大流行期间保障公众健康提供关键工具。灵敏、选择性和定量检测通常需要复杂的实验室方法和仪器来实现一致的结果；然而，该项目推进了简化流程的技术。抗体检测提供了以前感染的信息；一种检测低浓度存在的简单工具可以更好地进行检测，以管理社交距离需求。提出的技术旨在使针对SARS-Cov-2的两种抗体的血液检测变得简单和定量。该设备将开发为不需要复杂的样品准备就可以直接采集患者样本的设备，并将开发用于选择性检测SARS-CoV-2抗体的独特试剂。这项小型企业技术转移（STTR）第一阶段项目旨在开发下一代低成本护理点免疫测定技术，直接应用于传染病检测。这里提出的技术结合了一种新的方法来控制毛细流驱动系统，应用于一次性设备中传统ELISA的步骤。在这个项目中开发的设备将检测患者样本中的SARSCoV-2特异性抗体，并将能够提供有关患者免疫反应阶段的信息。此外，与传统的侧流检测相比，将elisa样酶扩增技术应用于护理点设备将提供更高的灵敏度和选择性，从而提高检测灵敏度并改善早期感染的检测。免疫测定将用未鉴定的患者样本进行评估，并与最先进的基于实验室的检测方法进行比较。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。